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Abstract
Although non-Hodgkin’s lymphoma (NHL) is a frequent cancer worldwide, primary cen-
tral nervous system (CNS) lymphoma (PCNSL) is a rare presentation, with an incidence 
of less than 0.5 per 100,000 persons-years in the western world. In the vast majority of 
cases, it has the histology of a diffuse large B-cell lymphoma (DLBCL) and is a hardly cur-
able disease with high relapse risk. Therapeutic options are limited by blood-brain barrier 
penetration of drugs and because of its low-incidence high-grade evidence from large 
studies is lacking, current management being based on reports on rather small cohorts. 
The current standard first-line treatment for PCNSL consists of high-dose methotrexate 
(HD-MTX) in combination with a variety of drugs and consolidation whole-brain radio-
therapy, the latter being progressively replaced by chemotherapy. For patients relapsing 
after first-line treatment, intensive chemotherapy with autologous stem cell support is 
a feasible and relatively safe salvage therapy. In the present chapter, we briefly discuss 
primary central nervous system lymphoma management and review current therapeu-
tic options and evidence-based recommendations. We discuss the role of whole-brain 
radiotherapy (WBRT) and new prospects to avoid this side effect-ridden approach. Also, 
we will look at new therapeutic approaches currently under investigation, including 
immunotherapy.
Keywords: PCNSL, primary cerebral tumor, aggressive lymphoma, whole-brain 
radiotherapy, blood-brain barrier
1. Introduction
One of the deadliest hematologic malignancies of our days, primary central nervous system 
(CNS) lymphoma (PCNSL), is a major unmet in oncology, with an outcome similar to that 
of acute leukemia, and a commonly used phrase to coin this poor prognosis states that the 
majority of patients die of their disease.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Of all primary CNS tumors, PCNSL represents a small percentage of around 4% in the United 
States [1]. With the exception of rare, anecdotal reports of primary CNS Hodgkin’s lymphoma, 
they are extranodal non-Hodgkin’s lymphomas (NHLs), the vast majority being of aggres-
sive, diffuse large B-cell type. According to the European Cancer Observatory’s (EUCAN) 
national estimates report on cancer incidence in Europe, the mean EU 27 incidence in 2012 of 
brain and CNS tumors was of 6.9 per 100,000 persons, ranging from a high of 11.9 in Sweden 
to a low of 5 in Hungary, allowing for an estimate of around 0.3 new cases of PCNSL per 
100,000 persons in 2012 across the EU.
The percentage of PCNSL presentation among all NHL cases is estimated at 2–3% [2]. More 
than 90% of PCNSL are diffuse large B-cell lymphomas (DLBCLs), other histological forms 
encountered being Burkitt’s and lymphoblastic lymphomas (5%) and marginal zone and 
T-cell NHL (3%) [3]. These low-incidence figures underscore the difficulty in patient accrual 
for clinical studies and, implicitly, for the formulation of evidence-based recommendations. 
Therapeutic advance is thus difficult, in a tumor ranked as one of the deadliest lymphomas, 
with a present estimated cure rate lower than 50%. The 2016 World Health Organization clas-
sification update of lymphoid neoplasms lists primary DLBCL of the central nervous system 
as a distinct entity among mature lymphoid neoplasms [4].
The etiology of PCNSL is unknown, as with the majority of cancers. However, increased inci-
dence is observed in HIV infection, PCNSL being, with 15–20% of all cases, one of the favorite 
presentations of AIDS-related lymphomas. The high incidence of PCNSL in AIDS patients 
declined with the advent of the contemporaneous highly active antiviral therapy, and an 
improvement in its prognosis was noted, as well [2]. An increased incidence is also observed 
in other immunosuppressed patients, notably in recipients of allogeneic transplantation 
on long-term immunosuppressive therapy. Although the spread of HIV infection offered a 
tempting explanation for the continuous increase in PCNSL (and NHL overall) incidence 
reported over the last decades of the twentieth century, the trend remains positive even after 
subtracting AIDS patients. As with many cancers, incidence of PCNSL increases with age, and 
it is estimated that approximately a half of the patients are over 65 years of age, with limiting 
implications in intensive management options. The disease favors men, with a 2:1 male to 
female gender ratio.
In the next sections, we will review the pathogenesis and diagnostic workup, as well as the 
current treatment paradigm for PCNSL. Novel therapeutic approaches currently under inves-
tigation will be also discussed
2. Pathobiology of PCNSL
Primary central nervous system lymphoma (PCNSL) has been historically known by many 
other names, including reticulum cell sarcoma, diffuse histiocytic lymphoma, and microg-
lioma. The proliferation of names reflects initial uncertainty about the cell of origin. PCNSL 
is in the overwhelming majority of cases an aggressive extranodal diffuse B-cell lymphoma. 
The cell of origin of the tumor obviously belongs to the lymphoid lineage, but the lympho-
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matous histology of PCNSL was established only during the 1970s. Before that, PCNSL was 
regarded as a microglioma or reticulum cell sarcoma. The lack of a precise histological defi-
nition of the disease did not, however, impact on therapy outcomes in that era, as the sole 
therapeutic modality employed for brain tumors, besides surgery, was brain radiotherapy [5]. 
Evolution in the understanding of the pathobiology of PCNSL lagged behind that of nodal 
lymphomas because of the dame reasons that hampered therapeutic evolution, namely, the 
rarity of the tumor.
PCNSL is, in an overwhelming majority of approximately (95%) of cases, an aggres-
sive extranodal diffuse large B-cell lymphoma (DLBCL) [6]. Other histologies have been 
described including lymphoma of T-cell origin, lymphoblastic lymphoma, Burkitt lym-
phoma, mucosa-associated lymphoid tissue (MALT), and marginal zone lymphoma (MZL) 
[7, 8]. Studies have generally focused on the features of primary DLBCL arising in the brain. 
Based on overexpression of B-cell lymphoma 6 (BCL-6) protein and V(H) gene sequence 
mutational status, PCNSL was thought to be of germinal center (GC) origin [9–11]. More 
recent immunohistochemical studies have shown that at least 95% of cases stain positive 
for MUM-1, regardless of their BCL-6 status; therefore, the majority have an activated B-cell 
(ABC) profile [12].The immunoprofile association with clinical outcome was evaluated, and 
high BCL-6 expression is usually associated with poor prognosis factors (elderly patients, 
high ECOG performance status) and correlates with refractory disease and shorter progres-
sion-free and overall survival [12, 13].
More recently, important progress has been made on the transcriptional profile of PCNSL. 
Overexpression of MYC, high expression of miRNA involved in MYC pathway, and MYC 
translocations have all been identified and seem to have an important role in this disease 
pathogenesis [13–15]. Other common genomic aberrations include loss of chromosome arm 
6q and losses on 6p21 involving tumor suppressor genes, regulators of B-cell differentiation, 
and NF-κB signaling [16, 17]. In addition, activating mutations of CARD11 and MyD88 are 
recurrent in PCNSL and support the aberrant activation of NF-κB pathway [18, 19]. Given the 
distinct genomic features and the necessity of an adapted treatment, different from its sys-
temic counterpart, PCNSL is now recognized as a distinct subtype of large B-cell lymphoma 
by the WHO [6, 20].
The selective tropism and whether PCNSL arises in the central nervous system (CNS) or out-
side the brain are still unresolved issues. The initial hypothesis was that B cells transform 
outside the CNS and due to certain adhesion molecules and chemokines, the modified lym-
phomatous cells have neurotropism and are preserved in the brain tissue [21]. Moreover, 
high chemokine CXCL-13 concentration in the cerebrospinal fluid (CSF) of PCNSL patients 
correlates with adverse prognosis and together with IL-10 are highly specific for the diagnosis 
of CNS lymphoma [22, 23].
The theory of development of neurotropic lymphomatous cells outside the brain was 
mainly based on the information that there is a lack of classical lymphatic drainage sys-
tem in the CNS. A fundamental discovery that could change these assumptions about the 
pathogenesis of PCNSL was recently published and reports the presence of functional lym-
phatic vessels lining the dural sinuses, able to carry immune cells from the CSF to the deep 
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cervical lymph nodes [24]. There is an ongoing controversy on the pathobiology of PCNSL, 
and new insights, which could change the current understanding of this disease group, 
are expected.
3. Clinical presentation, diagnosis and workup
The clinical presentation of PCNSL reflects its localization and typically consists of neurologic 
symptoms, which can be extremely polymorphic, depending on the tumor site. Psychiatric 
and ocular/visual manifestations are also common. Usually, these symptoms prompt neuro-
logic imaging which points to the tumor. Despite significant progress in imaging techniques 
and in the interpretation, there is a significant risk in attributing too much diagnostic power 
to neuroimaging, succumbing to the temptation to formulate a diagnosis based on tumor 
appearance. Statistically, the most frequent localization of PCNSL is supratentorial and peri-
ventricular, accounting for approximately 80% of cases, and 60% of PCNSL are presenting 
as a single mass at diagnosis, but leptomeningeal, cerebellar, and intraocular presentations 
are not uncommon. CSF cytology is positive demonstrating meningeal involvement in 16% 
of cases, but only rarely (<5% of cases) is leptomeningeal disease present without a cerebral 
lesion. Primary spinal cord presentation is extremely rarely encountered [3]. Eye involve-
ment is seen in up to 20% of patients, either as a primary localization or accompanying other 
CNS localizations. Also, subsequent development of brain lesions by spread from an initial 
intraocular localization is not uncommon [25]. Symptoms at presentation vary according to 
the tumor localization and may include headache, lethargy, visual disturbances, and focal 
neurological signs, while B symptoms are extremely uncommon [3].
The timely and correct diagnosis of primary CNS lymphoma can be significantly hampered by 
the administration of corticosteroid therapy, which occurs frequently in the neurological setting, 
where patients are likely to be referred because of their clinical presentation. Response to corti-
costeroid therapy has been and still is wrongly regarded as a major argument sustaining a lym-
phoma diagnosis in patients with brain tumors. Although corticosteroids are extremely active 
in lymphomas and can lead to a significant response and, sometimes, to the disappearance of 
the initial tumor, other histological types of primary CNS tumors may respond well to systemic 
corticosteroids, and thus response to corticosteroids cannot be regarded as an argument for the 
lymphomatous origin of the tumor. As with the vast majority of solid cancers, the correct positive 
diagnosis is anatomopathological (with rare exceptions discussed below) and involves the obten-
tion of a bioptic fragment of the tumor. There is no evidence that surgical tumor removal is benefi-
cial in lymphomas, and, thus, current evidence-based guidelines recommend a minimal invasive 
diagnostic approach for suspected CNS lymphoma, which is usually a stereotactic biopsy.
PCNSL workup consists of positive diagnosis and the evaluation of disease extension, patient 
status, prognostic markers, as well as treatment tolerance.
Clinical evaluation must include neurological examination, a general clinical exam, and per-
formance status. Both ECOG/WHO score and Karnofsky performance status scale are used to 
assess status by different guidelines.
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Imaging. In practice, it is not infrequent for a cerebral CT scan to be the first brain examination 
to describe the lymphoma, because of the typical patient presentation with neurological symp-
toms with a CT scan being employed to rule out ischemic or hemorrhagic stroke (Figure 1). 
Whole-brain MRI is the first step to sustain a suspicion of brain tumor, and it allows for the 
assessment of local extension of the brain tumor, as well as for the preparation of a minimal 
invasive bioptic approach for diagnosis. The MRI appearance can strongly suggest a lym-
phomatous nature of the tumor (Figures 2–6). Figure 7 demonstrates the MRI appearance of 
a very good partial response after first-line chemoimmunotherapy, and Figures 8–10 depict 
MRI appearance of a multifocal, bilateral relapse at 2 years. Complementary chest-abdominal-
pelvic CT scan is the standard investigation for the exclusion of systemic disease, but PET-CT 
can replace it when available. Testicular examination including ultrasound may complete 
imaging, as testicular involvement is more frequent in cerebral lymphomas.
Figure 1. Nonenhanced CT of the head at presentation, axial slice at the level of the convexity, showing a single right 
subcortical frontoparietal mass. The lesion appears isodense to gray matter (suggestive for CNS lymphoma) surrounded 
by vasogenic edema. Please note gray matter sparing.
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Figures 2–6. MRI of the brain, initial presentation. Axial T2, DWI/ADC, T1, T1 postcontrast, coronal T1 postcontrast. 
Right centrum semioval focal intra-axial mass is shown. The lesion is hypointense in T2, with vasogenic edema 
(Figure 2), restricted diffusion (Figure 3), and hypo-T1 (Figure 4) with homogeneous enhancement (Figures 5 and 6). 
MRI appearance is suggestive of hypercellularity (low T2, low ADC) as seen in CNS lymphoma.
Figure 3. 
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Figure 4. 
Figure 5. 
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Figure 7. Follow up MRI of the brain at 3 months (post-HD-MTX and rituximab treatment). Axial T2, T1 postcontrast. 
Excellent treatment response with nearly complete resolution of the initial lesion. Please note the presence of small 
amounts of products within the lesion related to the initial stereotactic biopsy.
Figure 6. 
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Figures 8–10. Brain MRI axial T2, T1 with contrast. Recurrence at 18 months, post-HD-MTX/rituximab/temozolomide 
and whole-brain radiation treatment. Bilateral tumor recurrence, with new lesions, similar in MRI appearance to the 
initial lesion. Please note the typical distribution in the deep hemispheric white matter and near the corpus callosum. 
Please note extensive diffuse postradiation white matter changes.
Figure 9. 
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Eye slit lamp examination is an integral part of the tumor extension workup, because of the 
frequent ocular involvement, and can prompt for subsequent imaging approaches like MRI. 
Also, if eye examination is positive for involvement, a vitreous biopsy can replace the brain 
biopsy and allow for a positive diagnosis.
Corticospinal fluid (CSF) examination by lumbar puncture should be performed in cases 
where it can be performed safely, which represents the majority of patients, as judged by 
the imaging and eye examinations. Cytology of CSF is rarely positive in PCNSL. However, 
cytologic and flow cytometric examination, as well as clonality assays, is warranted, and 
if evidence for lymphoma is strong enough by this approach, the brain lesion biopsy may 
become unnecessary. Also, there are new proposals for diagnostic approaches, which investi-
gate CSF levels of interleukin (IL)-10, CXCL13, or micro RNAs (miRs) to sustain the suspicion 
of lymphoma, currently under investigation [23].
Histological examination of a tumor biopsy is the standard diagnostic approach. Biopsies 
should be as noninvasive as possible, and stereotactic biopsy is the best choice. Large tumor exci-
sion does not improve disease prognosis, can lead to significant neurologic sequelae, and also 
can delay the onset of treatment because of the surgical trauma and the risk of complications.
Figure 10. 
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Laboratory tests include:
—Full blood count plus differential.
—Viral testing: HIV (mandatory, because of an increased PCNSL incidence in HIV-infected 
patients), hepatitis B and hepatitis C (especially if administration of immunotherapy is con-
templated which can lead to viral reactivation or flaring).
—Basic pretherapeutic blood biochemistry to evaluate chemotherapy tolerance: liver func-
tion tests, kidney function, and electrolytes. Lactate dehydrogenase levels are of prognostic 
significance.
3.1. Staging and prognostic markers
There currently is no dedicated staging system for PCNSL. Using the Ann Arbor staging, 
PCNSL is usually a stage IEA lymphoma and as such is of limited clinical relevance. Prognostic 
indices commonly employed are the International Prognostic Index (IPI) and age-adjusted IPI, 
both including staging as a criterium. The International Extranodal Lymphoma Study Group 
has proposed a prognostic score for PCNSL based on five parameters: age>60 years, ECOG 
performance status>1, increased lactate dehydrogenases, elevated CSF protein levels, and deep 
brain localization of the tumor and proposed three prognostic groups: good risk (0–1 factors 
present), intermediate risk (2–3 factors), and high risk (3–4 factors). Although at the time of 
publication, in 2003, this score could discriminate well the outcomes of the three groups, it is of 
limited clinical use, because of the scarcity of therapeutic options limiting treatment adaptation 
according to the calculated score.
Performance status either according to ECOG/WHO or Karnofsky performance status scale is 
a useful indicator of the patient’s tolerance profile for aggressive approaches and may help in 
the adaptation of dose intensity of therapeutic regimens.
4. Treatment of PCNSL
Prognosis of PCNSL is dismal, and therapeutic results are rather poor, especially when com-
pared to other aggressive lymphomas. The outcome has witnessed a constant improvement 
over the last decades. As with other malignancies, it is unclear to what extent this improvement 
can be credited to a progress in anticancer agents, which have not dramatically changed for 
PCNSL until recently and how much of the progress should rather be attributed to a constant 
improvement in supportive measures, including the management of treatment-related compli-
cations. The development of better antibiotics and antifungals, as well as the advent of hemato-
poietic stimulating agents, allowed for drug dose and regimen intensity escalations and reduced 
treatment-related mortality, which could explain the ascending trend of therapeutic results.
As with other hematologic cancers, the treatment paradigm of PCNSL involves the induction 
of a complete remission (CR), followed by consolidation strategies aimed at preventing dis-
ease recurrence. Radiotherapy was, historically, the first nonsurgical therapeutic approach in 
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lymphoma. Due to the particularities of CNS lymphoma, whole-brain radiotherapy (WBRT) 
is the standard radiation therapy approach and may include a boost to the involved CNS area. 
Unfortunately, WBRT is not only highly ineffective in curing lymphoma outside a combina-
tion with systemic treatment, but it is also associated with severe immediate and delayed 
neurotoxicity, including alteration of cognitive functions, sometimes severe and irreversible.
The addition of methotrexate (MTX)-based Systemic therapy has allowed in the 1970s for 
a significant improvement in cerebral lymphoma outcome, while the classical combination 
chemotherapy is used for nodal NHL, consisting of CHOP or CHOP-like regimens, dem-
onstrating unsatisfactory results in PCNSL [26]. The standard first-line regimens today are 
constantly including high-dose MTX (HD-MTX) as the backbone of chemotherapy. MTX, 
aracytine; alkylating agents like busulfan, carmustine, lomustine, thiotepa, and ifosfamide; 
and platinum compounds have demonstrated their ability to cross the blood-brain barrier in 
efficient amounts. Although the CNS/CSF to plasma ratio for systemic MTX is low at around 
5%, the CNS penetrance is sufficient for achieving therapeutic results but only at high sys-
temic doses which usually start at 1.5 g/m2 and go up to above 8g/m2 [27]. An algorithm of the 
typical frontline treatment of PCNSL is presented in Figure 11.
Figure 11. Treatment algorithm for newly diagnosed patients, according to the National Comprehensive Cancer 
Network [45] and European Society for Medical Oncology [29] evidence-based guidelines.
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4.1. First-line induction therapy
The remission induction treatment for PCNSL is chemotherapy based, with anti-CD20 
immunotherapy being added in recent years. MTX, which had been previously used in 
high doses with leucovorin rescue in the management of CNS involvement of acute lym-
phoblastic leukemia has been reported as efficient in CNS lymphoma, either primary 
or secondary to systemic disease, in the late 1970s, at doses ranging from 1 to 7.5 g/m2. 
Subsequently, HD-MTX became the backbone of PCNSL induction therapy and currently 
used doses which range from 3 to 8 g/m2, and it was demonstrated that systemic MTX at 
doses over 3.5 g/m2 alleviates the need for concomitant intrathecal administration of the 
drug [6, 28]. Although a great step forward in PCNSL, single-agent MTX achieved com-
plete remission (CR) rates of only approximately 30% as frontline induction therapy [29]. 
The addition of cytarabine to MTX allowed for an improvement of CR rates to 46% versus 
18% with MTX as single agent with an overall response rate of 69% versus 40% in one of 
the few randomized prospective studies performed [26]. The addition of alkylating agents 
or vincristine to MTX and cytarabine did not alter induction treatment efficiency [29, 30]. 
The optimal number of cycles of induction chemotherapy is not clearly established, but six 
to eight two-weekly administrations are currently used [6]. For the frail or elderly patients 
not able to withstand intensive regimens, alkylating agents like temozolomide and lomus-
tine are proposed, with temozolomide achieving CR rates of nearly 50%, comparable to 
HD-MTX-based regimens [31].
Association of immunotherapy with anti-CD20 antibodies, which greatly improves out-
comes in nodal B-cell NHL, was not expected to be efficient in PCNSL, as rituximab is a 
macromolecule unable to bypass the blood-brain barrier (BBB). CSF concentrations of ritux-
imab are normally less than 1% of systemic concentrations but can reach higher levels when 
coadministered with chemotherapy possibly due to BBB disruption. Inclusion of rituximab 
in the induction therapy of PCNSL has yielded controversial results and is not a current 
evidence-based guideline recommended standard practice, but is routinely used by many 
hematologists. Another approach currently under investigation is the intrathecal adminis-
tration of rituximab, either by lumbar puncture or via an Ommaya reservoir. Adjunction 
of rituximab to chemotherapy was reported to significantly improve PCNSL outcome in a 
recently published retrospective study [32], and one of the largest prospective randomized 
studies in PCNSL, including 227 patients of up to 70 years of age, recently reported prelimi-
nary results showing that rituximab with or without thiotepa, plus HD-MTX and cytarabine, 
achieved superior remission rates as compared to HD-MTX and cytarabine alone, and the 
authors proposed the thiotepa, rituximab, plus HD-MTX and cytarabine (MATRix) regimen 
as the new standard induction regimen for fit patients [33]. Qian et al. reported interesting 
results with R-IDARAM in combination with intrathecal chemotherapy for newly diagnosed 
PCNSL patients. Treatment consisted of six cycles, administered at 3 weeks of interval, of 
rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2 (day 2 and 3), dexamethasone 100 mg/m2 
(12 h infusion on days 2, 3, and 4), cytarabine 1 g/m2 (1 h. infusion on days 2 and 3), MTX 2 g/
m2 (6 h infusion on day 4 with folinic acid rescue), intrathecal rituximab 10 mg, MTX 15 mg, 
dexamethasone 5 mg ,and cytarabine 50 mg once a week. The reported CR rate for the 19 
patients treated was an impressive 89% [34].
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4.2. Consolidation therapy
Initially used as the single available therapeutic approach besides tumor excision, WBRT in 
dosed of 40–45 Gy became the standard consolidation regimen after the advent of methotrexate-
based therapies. WBRT is a side effect-ridden approach, with high risk of neurotoxicity includ-
ing cognition and memory impairment, brain atrophy, leukoencephalopathy, dementia, and 
endocrine abnormalities estimated at 25–35% at 5 years and up to 30% mortality rate [30, 35].
Dahlborg et al. published in 1996 what they called a first example of a durable response in 
PCNSL patients with chemotherapy alone, reporting, in a 58 PCNSL patient cohort retro-
spective analysis, similar results in patients treated with chemotherapy alone versus WBRT 
followed by chemotherapy [36]. Since, there has been a continuous quest for improving sys-
temic therapy to alleviate the need for brain irradiation. Although the advent of combination 
chemotherapy rendered radiotherapy obsolete in many types of lymphoma, it is still an inte-
gral part of some currently employed treatment regimens, especially in Hodgkin’s lympho-
mas and their histologically close relative, primary mediastinal B-cell lymphoma. In PCNSL, 
WBRT including the eyes is used because the diffuse infiltrative pattern of lymphoma, with 
focal radiotherapy resulting in a higher recurrence rate. Higher doses of irradiation did not 
improve the results and was associated with more severe neurotoxicity. A meta-analysis was 
published in 2001 investigating radiotherapy and optimal induction chemotherapy in PCNSL; 
radiation doses higher than 40 Gy did not show improved OS, and there was no outcome dif-
ference between immediate and delayed consolidation WBRT in patients achieving CR after 
chemotherapy [37]. As results of trials investigating the omission of radiotherapy as a con-
solidation therapeutic modality are conflicting, to date there are no definitive answers to this 
question. The majority of local protocols omit, however, WBRT as part of the first-line treat-
ment of PCNSL, but its importance in relapsed/refractory disease is clearly established [5]. 
Also, WBRT at doses of 40–50 Gy is an option for patients where chemotherapy is contraindi-
cated. In patients with the usual DLBCL aggressive histology, this strategy has a merely pallia-
tive role, with a chance of CR of less than 20% and short overall survival. However, in patients 
with the rarer, indolent lymphoma histology including marginal zone, lymphoplasmacytic, 
lymphocytic, plasmocytoma, and Hodgkin’s, WBRT can be used with curative intent.
4.3. Bone marrow transplantation
High-dose chemotherapy followed by autologous stem cell transplantation (HDCT/ASCT) is 
usually reserved for the relapsed/refractory setting. The 2-year overall survival rate is less than 
50%. Usually, conditioning regimens are thiotepa based and busulfan based, but the BEAM 
conditioning regimen typically employed for nodal lymphomas is still used in PCNSL, despite 
its low BBB penetrance. HDCT/ASCT has been recently investigated as a consolidation ther-
apy after high-dose MTX-based regimens, particularly to avoid the neurological risk of WBRT. 
There are ongoing trials to establish the role of ASCT as first-line consolidation therapy [38].
4.4. Second-line/salvage therapy
If the long-term disease-free survival in newly diagnosed PCNSL approaches 50%, in 
relapsed/refractory disease, the CR and overall survival rates are discouraging, and there 
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currently is no standard of care. Ideally, the second-line therapy should employ agents 
not used in frontline treatment and be followed by ASCT. If the first remission was longer 
than 12 months, HD-MTX-based re-induction can be attempted, followed by either autolo-
gous transplantation or WBRT, depending on which of those has been used in the frontline 
approach
Alkylating agents such as temozolomide, thiotepa, or lomustine with or without rituximab 
are another therapeutic option in this setting. Like with all cancers, patient inclusion on a clin-
ical trial is highly recommended. Novel therapeutic approaches, some of which are discussed 
below, are either under investigation or in development, in a disease group where therapy 
represents a major unmet of current hematologic clinical practice.
4.5. Novel approaches in PCNSL treatment
Ibrutinib is a novel agent acting as a covalent Bruton tyrosine kinase inhibitor, belonging to 
the B-cell receptor signaling inhibitors and showing remarkable activity in B-cell malignancy. 
It has been approved by the Food and Drug Administration and the European Medicines 
Agency in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s mac-
roglobulinemia, and trials in other B-cell malignancies are ongoing. Ibrutinib was shown 
to penetrate the blood-brain barrier and to be active in cerebral involvement of mantle cell 
lymphoma and Waldenstrom’s macroglobulinemia [39, 40]. Recently, preliminary results in 
relapsed/refractory PCNSL and secondary CNS lymphoma were available from a phase I 
study, where, in a small group of 10 patients, the drug demonstrated a good tolerance profile 
and an overall response rate of 78% [41].
Lenalidomide and other immunomodulatory drugs. After thalidomide, the infamous sedative 
drug withdrawn during the 1970s because of its teratogenic effects, was reinvented as an 
effective and well-tolerated anti-myeloma oral drug two decades ago, spice-up succes-
sors like lenalidomide and pomalidomide with better anti-myeloma activity and less side 
effects were developed. Although their efficacy was initially credited to anti-neoangioge-
netic effects, hampering tumor growth, other immune-enhancing pathways of action were 
subsequently characterized, and the class is currently referred to as immunomodulatory 
drugs (IMiDs) and was shown to be active not only in B-cell malignancies but also in par-
ticular myeloproliferative neoplasms and myelodysplastic syndromes. Lenalidomide 
has shown efficacy in aggressive B-cell lymphomas like DLBCL or mantle cell lymphoma 
and also as a graft-versus-disease enhancer in the post-allogeneic transplantation setting. 
Lenalidomide has the advantage of a good safety profile and tolerance, making it extremely 
useful in elderly or frail patients, not able to withstand intensive therapeutic approaches 
[42]. Lenalidomide is being investigated in PCNSL and has been shown to penetrate the 
BBB, with good intraventricular, intraocular, and brain tissue penetrance. Lenalidomide has 
been administered either as a single agent or in combination with systemic or intraventricu-
lar rituximab. Although efficacy of lenalidomide was only reported in isolated case reports 
or small case series and phase I trials, it seems to be an interesting agent credited with great 
expectations especially in the frail PCNSL patients where therapeutic options are extremely 
limited [43, 44].
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5. Conclusions
PCNSL is presently one of the deadliest lymphomas, with a cure rate estimated as being 
lower than 50%, and therapeutic improvement lags behind that of nodal lymphomas due 
to the rarity of the disease, making patient accrual for prospective studies difficult. There 
is ongoing controversy about the pathobiology of PCNSL, and consensus evidence-based 
guidelines for its management are difficult to formulate. The current treatment for PCNSL 
consists of combination chemotherapy with a high-dose methotrexate-based backbone. 
Brain radiotherapy has demonstrated its efficiency as a consolidation regimen, but newer 
approaches tend to avoid radiotherapy and replace it with chemoimmunotherapy includ-
ing high-dose therapy with autologous stem cell support, because of the serious side effects 
of the former. Despite significant progress, PCNSL therapy remains a major unmet for 
hematologists, and the development of new therapeutic approaches is warranted.
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